Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR.
- Published in:
- Clinical Infectious Diseases, 2025, v. 80, n. 5, p. 1005, doi. 10.1093/cid/ciae615
- By:
- Publication type:
- Article
Works by Harrington, Patrick R
Results: 8
1
2
Reply to Merli et al.
- Published in:
- 2016
- By:
- Publication type:
- Letter to the Editor
3
Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, n. 6, p. 974, doi. 10.1093/cid/civ419
- By:
- Publication type:
- Article
4
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
- Published in:
- 2015
- By:
- Publication type:
- Letter to the Editor
5
Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy.
- Published in:
- Clinical Infectious Diseases, 2013, v. 56, n. 10, p. 1466, doi. 10.1093/cid/cit025
- By:
- Publication type:
- Article
6
Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 2, p. 327, doi. 10.1093/cid/ciz385
- By:
- Publication type:
- Article
7
Dynamics of Simian Immunodeficiency Virus Populations in Blood and Cerebrospinal Fluid over the Full Course of Infection.
- Published in:
- Journal of Infectious Diseases, 2007, v. 196, n. 7, p. 1058, doi. 10.1086/520819
- By:
- Publication type:
- Article
8
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials--United States and International Sites, 2021-2022.
- Published in:
- MMWR: Morbidity & Mortality Weekly Report, 2023, v. 72, n. 51, p. 1365, doi. 10.15585/mmwr.mm7251a2
- By:
- Publication type:
- Article